CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 1.62×, higher than 95% of its Biotechnology peers (median 0.09×)
- FinancialsAltman Z-Score 0.91: distress zone
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
636.69MGBP869.28M · vs all stocks (USD)
Revenue (TTM)
168.74MGBP230.38M · vs all stocks (USD)
Profit Margin
-17.85%vs Biotechnology peers
Beta
1.10xvs all stocks
52-Week Change
-5.40%vs all stocks
Market Capitalization
636.69MGBP869.28M · vs all stocks (USD)
Enterprise Value
658.61MGBP899.21M · vs all stocks (USD)
Forward P/E
-567.08xvs Biotechnology peers
Price to Sales (TTM)
3.61xvs Biotechnology peers
Price to Book (MRQ)
6.65xvs Biotechnology peers
Enterprise to Revenue
3.90xvs Biotechnology peers
Enterprise to EBITDA
-36.06xvs Biotechnology peers
Profit Margin
-17.85%vs Biotechnology peers
Operating Margin
-7.88%vs Biotechnology peers
Return on Assets (TTM)
-6.98%vs Biotechnology peers
Return on Equity (TTM)
-40.37%vs Biotechnology peers
Revenue (TTM)
168.74MGBP230.38M · vs all stocks (USD)
Revenue per Share (TTM)
1.51GBPUpdated Aug 22, 2026Quarterly Revenue Growth
22.50%vs Biotechnology peers
Gross Profit (TTM)
65.98MGBP90.08M · vs all stocks (USD)
EBITDA (TTM)
-18.26MGBP-24.93M · vs all stocks (USD)
Net Income (TTM)
-30.13MGBP-41.13M · vs all stocks (USD)
Operating Cash Flow (TTM)
507.00KGBP692.21K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-13.25KGBP-18.09K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
0.00GBPFY2025 · Dec 31, 2025Revenue
168.74MGBPFY2025 · Dec 31, 2025Cost of Goods Sold
102.76MGBPFY2025 · Dec 31, 2025Gross Profit
65.98MGBPFY2025 · Dec 31, 2025Operating Income
-32.96MGBP-45.00M · vs all stocks (USD)
Pre-tax Income
-31.94MGBPFY2025 · Dec 31, 2025Income Tax Expense
-1.29MGBPFY2025 · Dec 31, 2025Net Income
-30.64MGBPFY2025 · Dec 31, 2025EBIT
-17.43MGBPFY2025 · Dec 31, 2025EBITDA (Income Statement)
-7.37MGBPFY2025 · Dec 31, 2025Research & Development
5.06MGBPFY2025 · Dec 31, 2025Selling, General & Administrative
36.76MGBPFY2025 · Dec 31, 2025Other Operating Expenses
57.70MGBPFY2025 · Dec 31, 2025Non-operating Interest Income
5.18MGBPFY2025 · Dec 31, 2025Non-operating Interest Expense
14.50MGBPFY2025 · Dec 31, 2025EPS (Basic)
-26.92GBPFY2025 · Dec 31, 2025EPS (Diluted)
-26.92GBPFY2025 · Dec 31, 2025Basic Shares Outstanding
111.92MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
111.92MSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
517.00KGBPFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00GBPFY2025 · Dec 31, 2025Operating Cash Flow
-33.05MGBPFY2025 · Dec 31, 2025Free Cash Flow
-37.81MGBPFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
96.88MGBPFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-31.94MGBPFY2025 · Dec 31, 2025Stock-based Compensation
4.68MGBPFY2025 · Dec 31, 2025Other Non-cash Items
-465.00KGBPFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-21.66MGBPFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
16.33MGBPFY2025 · Dec 31, 2025Capital Expenditures
-4.76MGBPFY2025 · Dec 31, 2025Net Acquisitions
-3.34MGBPFY2025 · Dec 31, 2025Net Investing Cash Flow
-8.10MGBPFY2025 · Dec 31, 2025Long-term Debt Issuance
41.95MGBPFY2025 · Dec 31, 2025Long-term Debt Payments
-38.77MGBPFY2025 · Dec 31, 2025Other Financing Charges
-2.00MGBPFY2025 · Dec 31, 2025Net Financing Cash Flow
59.24MGBPFY2025 · Dec 31, 2025Shares Outstanding
120.75MSharesUpdated Aug 22, 2026Float Shares
60.83MSharesUpdated Aug 22, 2026% Held by Insiders
20.55%vs all stocks
% Held by Institutions
55.25%vs all stocks
Total Cash (MRQ)
96.90MGBP132.30M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.8020GBPUpdated Aug 22, 2026Total Debt (MRQ)
148.13MGBP202.24M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.62xvs Biotechnology peers
Current Ratio (MRQ)
2.20xvs Biotechnology peers
Book Value per Share (MRQ)
0.7560GBPUpdated Aug 22, 2026Total Assets
325.72MGBP444.71M · vs all stocks (USD)
Total Current Assets
185.65MGBPFY2025 · Dec 31, 2025Total Liabilities
234.37MGBPFY2025 · Dec 31, 2025Total Non-current Assets
140.07MGBPFY2025 · Dec 31, 2025Total Non-current Liabilities
150.15MGBPFY2025 · Dec 31, 2025Total Current Liabilities
84.22MGBPFY2025 · Dec 31, 2025Cash
96.88MGBPFY2025 · Dec 31, 2025Cash & Cash Equivalents
96.88MGBPFY2025 · Dec 31, 2025Accounts Receivable
22.69MGBPFY2025 · Dec 31, 2025Inventory
17.33MGBPFY2025 · Dec 31, 2025Accounts Payable
14.21MGBPFY2025 · Dec 31, 2025Short-term Debt
6.06MGBPFY2025 · Dec 31, 2025Long-term Debt
142.07MGBPFY2025 · Dec 31, 2025Common Stock (Book)
60.38MGBPFY2025 · Dec 31, 2025Retained Earnings
-422.35MGBPFY2025 · Dec 31, 2025Total Shareholders' Equity
91.35MGBP124.72M · vs all stocks (USD)
52-Week Low
441.50GBXUpdated Aug 22, 202652-Week High
962.00GBXUpdated Aug 22, 202652-Week Change
-5.40%vs all stocks
Beta
1.10xvs all stocks
50-Day MA
585.91GBXUpdated Aug 22, 2026200-Day MA
642.16GBXUpdated Aug 22, 2026Avg 10-Day Volume
1.31MSharesUpdated Aug 22, 2026Avg 30-Day Volume
744.59KSharesUpdated Aug 22, 2026Diluted EPS (TTM)
-0.2700GBPUpdated Aug 22, 20265 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Return on equity reads high on a balance sheet carrying a lot of debt against that equity.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Where is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
Sharp Decline With Volume And Volatility Expansion
A steep fall on heavy volume, leaving the price far below its peak.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 1.62×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 1.62Industry median: 0.09Industry P95: 0.88Peers compared: 261
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 132,302,634.93Total Debt (USD): 202,240,639.68Debt-to-Equity: 1.62
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.20Altman Z-Score: 0.91
Financial Health
Altman Z-Score 0.91: distress zoneCritical
Altman Z-Score: 0.91
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Amphastar Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Phathom Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Kaibao Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Theravance Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Replimune Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Eagle High Plantations Tbk
3 interpretationsElevated Leverage on Three DenominatorsElevated ROE With High Debt-to-Equity and Equity MultiplierWithin or Near the Altman Distress Zone
Shenzhen Bauing Construction Holding Group Co., Ltd.
3 interpretationsElevated Leverage on Three DenominatorsElevated ROE With High Debt-to-Equity and Equity MultiplierWithin or Near the Altman Distress Zone
Guangzhou Jinyi Media Corp.
3 interpretationsElevated Leverage on Three DenominatorsElevated ROE With High Debt-to-Equity and Equity MultiplierWithin or Near the Altman Distress Zone